· Published by Health Canada · Official notice
This is duplicated text of a letter from Bayer Inc. and Janssen Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
March 14, 2012
Subject: Association of fluoroquinolone antibiotics (AVELOX®, CIPRO®, CIPRO® XL, and LEVAQUIN®) with worsening of symptoms of myasthenia gravis in patients with myasthenia gravis
The manufacturers of the fluoroquinolone antibiotics (Bayer Inc. and Janssen Inc.) in consultation with Health Canada would like to inform you of important updates to the labelling for fluoroquinolone antibiotics (AVELOX®, CIPRO®, CIPRO® XL, and LEVAQUIN®).
Fluoroquinolone antibiotics are a class of prescription drugs used to treat certain types of bacterial infections in adults, such as respiratory tract infections, skin infections and urinary tract infections.
Healthcare professionals, patients and their caregivers should be aware of the following information:
Exacerbation of symptoms of myasthenia gravis was already included as an undesirable effect in earlier versions of the Product Monographs of Avelox®, Cipro®, Cipro® XL and LEVAQUIN®. To reinforce the warning, the Canadian Product Monographs (PMs) for the fluoroquinolone antibiotics have been updated in January 2012 to reflect potential for worsening of symptoms of myasthenia gravis in patients with myasthenia gravis. The corresponding generic Product Monographs are in the process of being updated to reflect these warnings. Myasthenia gravis is a rare, chronic (long-lasting and recurring) disease that causes progressive muscle weakness. Activity makes the muscle weakness worse, and symptoms generally improve with rest.
Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of worsening of myasthenia gravis in patients with myasthenia gravis or other serious or unexpected adverse reactions in patients receiving fluoroquinolone antibiotics should be reported to the manufacturer (Bayer Inc. or Janssen Inc.) or Health Canada.
For AVELOX®, CIPRO® and CIPRO® XL:
Bayer Inc.
77 Belfield Road
Toronto, Ontario
M9W 1G6
Toll-free telephone: 1-800-265-7382
E-mail: Canada.medinfo@bayer.com
For LEVAQUIN®:
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Toll-free telephone: 1-866-825-7122
E-mail: dsscan@joica.jnj.com
Fax: 1-866-767-5865
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Shurjeel Choudhri, MD FRCPC
Senior Vice President & Head,
Medical & Scientific Affairs
Bayer HealthCare Pharmaceuticals
Cathy Lau, PhD.
Vice President,
Regulatory and Quality
Janssen Inc.
All trademarks used under license.